-       Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax-       Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results-       Overview of the Phase 1b trial of R289 in patients with lower-risk MDS SOUTH SAN FRANCISCO, Calif., June 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today annou ...